Abstract: A sealant configured to saturate and seal a graphite plate, such as a type of graphite plate that may be used in a hydrogen (H2) fuel cell, wherein the sealant may be one or more, or a mixture, of ethoxylated monomers. In some embodiments herein the sealant does not have an acid or a surfactant. Also disclosed is a graphite sheet impregnated with a sealant.

Abstract: A stabilizer composition for producing a polymeric hollow article in a rotomolding process has stabilizing amounts of: (i) at least one chroman-based compound according to Formula (V): wherein at least one instance of R21 is OR27, R27 is COR?? or Si(R28)3, and R??, R22, R23 R24, R25 and R26 are as defined herein; (ii) at least one phosphite or phosphonite; and (iii) a basic co-additive selected from alkali metal or alkaline metal salts of higher fatty acids. A polymeric hollow article is made by a process comprising: a) filling a mold with a polyolefin and a stabilizing amount of the stabilizer composition described herewith; b) rotating the mold around at least one axis while heating the mold in an oven, thereby fusing the composition and spreading it to the walls of the mold; c) cooling the mold; and d) opening the mold to remove the resulting polymeric hollow article.

Abstract: Polyolefin compositions of a polyolefin, a chroman-based compound according to Formula (V): and a basic co-additive selected from alkali metal or alkaline metal salts of higher fatty acids are disclosed. Amounts of the chroman-based compound and the basic co-additive are selected to enhance processing stability of the polyolefin composition when subjected to extrusion, even in the absence of antistatic agents and organic phosphites and phosphonites. Masterbatch compositions of a first polyolefin, the chroman-based compound and the basic co-additive can be blended with a second polyolefin, identical to, or compatible with, the first polyolefin to form a stabilized polyolefin composition. Molded articles produced by molding the polyolefin compositions are also disclosed. R21, R22, R23, R24, R25, R26, and R27 are also described.

Abstract: The cycle time of polymer compositions subjected to a rotomolding process is improved (i.e.

Abstract: Stabilizer compositions having a chroman-based compound according to Formula (V): and their use in processes for stabilizing organic materials subject to degradation and/or discoloration due to the effects from light, oxygen and heat, and in processes for producing articles from organic materials blended therewith, are provided herein.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the cap analogs.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the cap analogs.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

Abstract: A system and method for measuring flow resistance of a fluid in a conduit is provided. The system generally includes a reservoir for containing the fluid, a pump connected to the reservoir for distributing the fluid through a conduit having a straight measurement section, one or more pressure sensors connected to the conduit for measuring the pressure of the fluid in the conduit at one end of the straight measurement section and an opposite end of the straight measurement section.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

Abstract: A respirator has one or more electrodes of e.g. conductive elastomer disposed on the surface of a face sealing member opposite to the surface which seals against the user's face. In use the integrity of the seal formed between the sealing member and the user's face is monitored by monitoring the electrical capacitance across that member between the electrode(s) and the user's face.

Abstract: The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.

Abstract: A modular outdoor cabinetry system that can be easily assembled from standardized, prefabricated parts, and can be modified or disassembled with ease. The system consists of corner posts and panels that can be assembled into cabinets of various sizes. The cabinets may be configured as standard cabinets having one or more opening doors or may be configured as specialty cabinets with different kits. A bar kit enables a cabinet to include a raised bar, a sink kit enables a cabinet to house a sink, a grill kit enables a cabinet to house a grill, a drawer kit enables a cabinet to include drawers, a refrigerator kit enables a cabinet to house a refrigerator and a trash can kit enables a cabinet to house a trash can. The cabinets are configured to enable the exterior of the cabinets to be changed in an easy manner.

Abstract: The present invention is directed to substituted triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.

Abstract: The present invention is directed to substituted triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.